A novel nanobody as therapeutics target for EGFR-positive colorectal cancer therapy: exploring the effects of the nanobody on SW480 cells using proteomics approach

Table 1 Proteomics data with differential expression ratio > 20 between gefitinib and R9VH36 groups

Accession	Protein name	q-value	Ratio: Gef/Con	p-value: Gef/Con	Ratio: R9VH36/Con	p-value: R9VH36/Con
Q8IVF2	Protein AHNAK2	0	100	1.78E⁻¹⁶	100	1.51E⁻¹⁶
Q9BVA0	Katanin p80 WD40 repeat-containing subunit B1	0.001	100	1.78E⁻¹⁶	100	1.51E⁻¹⁶
P02042	Hemoglobin subunit delta	0	0.728	3.01E⁻⁰²	25.327	1.51E⁻¹⁶
Q5VZ66	Janus kinase and microtubule-interacting protein 3	0.029	1.076	9.05E⁻⁰¹	21.564	1.51E⁻¹⁶
O15397	Importin-8	0	0.103	1.78E⁻¹⁶	21.246	1.51E⁻¹⁶
Q13315	Serine-protein kinase ATM	0	1.144	9.40E⁻⁰¹	0.01	1.51E⁻¹⁶
P54802	Alpha-N-acetylglucosaminidase	0	1.444	5.28E⁻⁰¹	0.01	1.51E⁻¹⁶
Q9HD67	Unconventional myosin-X	0	1.321	2.79E⁻⁰¹	0.01	1.51E⁻¹⁶
Q99707	Methionine synthase	0.002	1.307	4.10E⁻⁰¹	0.01	1.51E⁻¹⁶
Q9NX05	Constitutive coactivator of PPAR-gamma-like protein 2	0	1.305	7.79E⁻⁰¹	0.01	1.51E⁻¹⁶
Q969X5	Endoplasmic reticulum-Golgi intermediate compartment protein 1	0	1.26	3.73E⁻⁰¹	0.01	1.51E⁻¹⁶
A6NED2	RCC1 domain-containing protein 1	0	1.199	7.47E⁻⁰¹	0.01	1.51E⁻¹⁶
O15379	Histone deacetylase 3	0	0.935	9.76E⁻⁰¹	0.01	1.51E⁻¹⁶
O43156	TELO2-interacting protein 1 homolog	0	0.837	8.66E⁻⁰¹	0.01	1.51E⁻¹⁶
Q5NDL2	EGF domain-specific O-linked N-acetylglucosamine transferase	0	0.01	1.78E-¹⁶	0.01	1.51E⁻¹⁶

ISSN: 1477-5956